Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Comptoir cuts losses in first half despite subdued sales

(Sharecast News) - Restaurant group Comptoir almost broke even over the first half, reducing losses substantially despite only meagre sales growth, as the company kept a tight control on costs amid challenging conditions across the industry. Comptoir, which owns and operates 20 Lebanese, Middle Eastern and North African inspired restaurants with a further six franchise sites, reported a pre-tax loss of £0.07m for the six months to 29 June, compared with a loss of £2.21m the year before, with cost of sales and admin expenses falling sharply.

On an adjusted EBITDA basis, the company swung to a profit of £0.08m, from a loss of £0.57m the year before.

Revenues were 0.6% higher at £16.0m, with sales rising 1.6% on a like-for-like basis.

"The group's operational controls continue to be strengthened however economic conditions and cost pressures facing our brands are challenging. Despite an improving trend, this is still short of what we expect to be delivering," said chief executive Chaker Hanna.

Meanwhile, chair Richard Kleiner said the hospitality sector was still experiencing "significant challenges", owing to cost of living pressures and economic uncertainty.

"Prudent capital management has positioned the group well to face these challenges, and we continue to strive to offer a genuine value for money, exceptional experience for our guests despite what economic challenges are facing the industry in 2025 and beyond," Kleiner said.

Shares were 5.3% lower at 4.5p by 1050 BST.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.